Add-on Peginterferon Alfa-2a significantly reduces HBsAg levels in chronic hepatitis B, HBeAg-negative, genotype D patients fully suppressed on nucleot(s)ide analogues treatment: HERMES Study Interim Analysis

被引：0

作者：

Lampertico, Pietro ^{[1
]}

Brunetto, Maurizia R. ^{[2
,3
]}

Craxi, Antonio ^{[4
]}

Gaeta, Giovanni B. ^{[5
]}

Rizzetto, Mario ^{[6
]}

Palmieri, Giulio ^{[7
]}

Colombo, Massimo ^{[1
]}

机构：

[1] Univ Milan, Div Gastroenterol & Hepatol, Osped Maggiore Policlin, Milan, Italy

[2] Univ Hosp Pisa, Reference Ctr Chron Liver Desease, Liver Unit, Pisa, Italy

[3] Univ Hosp Pisa, HCC Tuscany Reg, Pisa, Italy

[4] Univ Palermo, Di Bi MIS, Palermo, Italy

[5] Univ Naples 2, Dept Internal Med, Sect Infect Desease, Naples, Italy

[6] Univ Turin, Dept Gastroenterol, Turin, Italy

[7] Roche SpA, Monza, Italy

来源：

HEPATOLOGY | 2014年 / 60卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

LB-31

引用

页码：1285A / 1286A

页数：2

共 50 条

[31] RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTS
Lampertico, P.
Vigano, M.
Di Costanzo, G. G.
Sagnelli, E.
Fasano, M.
Di Marco, V.
Boninsegna, S.
Farci, P.
Fargion, S.
Giuberti, T.
Rothe, V.
Regep, L.
Caputo, A.
Facchetti, F.
Colombo, M.
JOURNAL OF HEPATOLOGY, 2012, 56 : S207 - S208
[32] BASELINE HBSAG LEVEL AND ON-TREATMENT HBSAG AND HBV DNA DECLINE PREDICT SUSTAINED VIROLOGICAL RESPONSE IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA); AN INTERIM ANALYSIS
Takkenberg, Bart
Zaaijer, Hans L.
de Niet, Annikki
Weegink, Christine J.
Terpstra, Valeska
Koot, Maarten
Dijkgraaf, Marcel
Jansen, Peter L.
Janssen, Harry L.
Beld, Marcel
Reesink, Hendrik W.
HEPATOLOGY, 2009, 50 (04) : 538A - 539A
[33] BASELINE HBSAG AS PREDICTOR FOR HBSAG SEROCONVERSION IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A AND ADEFOVIR: FINAL RESULTS OF A PROSPECTIVE OPEN LABEL STUDY
Takkenberg, Bart
de Niet, Annikki
Zaaijer, Hans L.
Weegink, Christine J.
Terpstra, Valeska
Dijkgraaf, Marcel
Jansen, Peter L.
Rijckborst, Vincent
Janssen, Harry L.
Beld, Marcel
Reesink, Hendrik W.
HEPATOLOGY, 2011, 54 : 1039A - 1040A
[34] EXTENDED (2 YEARS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IMPROVES SUSTAINED RESPONSE RATES IN GENOTYPE D-PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B
Lampertico, P.
Vigano, M.
Di Costanzo, G.
Sagnelli, E.
Fasano, M.
Di Marco, V.
Boninsegna, S.
Farci, P.
Fargion, S.
Giuberti, T.
Iannacone, C.
Massetto, B.
Fedeli, P.
Colombo, M.
JOURNAL OF HEPATOLOGY, 2010, 52 : S45 - S45
[35] Outcome of treatment with peginterferon alfa-2a (40KD) in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B (CHB) in the real-world: interim analysis of data from the large European S-Collate cohort
Marcellin, Patrick
Curescu, Manuela G.
Piekarska, Anna
Mazur, Wlodzimierz W.
Hezode, Christophe
Guyader, Dominique
Jochum, Christoph
Foster, Graham R.
Ouzan, Denis
Cornberg, Markus
Bogdan, Manfred
Messinger, Diethelm
Cartier, Veronique
Petersen, Joerg
HEPATOLOGY, 2013, 58 : 656A - 657A
[36] On treatment prediction of post-treatment sustained response to Peginterferon alfa-2a for HBeAg-negative Chronic Hepatitis B (CHB) patients using HBsAg and HBV DNA levels at weeks 12 and 24: PERSEAS cohort final results
Goulis, Ioannis
Karatapanis, Stylianos
Akriviadis, Evangelos A.
Deutsch, Melanie
Dalekos, George N.
Raptopoulou-Gigi, Maria
Mimidis, Konstantinos
Germanidis, Georgios
Triantos, Christos K.
Drakoulis, Christos
Chounta, Athina
Vafiadis, Irene
Hatzis, Grigorios
Gagalis, Asterios
Vlachogiannakos, Jiannis
Zintzaras, Elias
Koulouris, Sokratis
Bakalos, George
Papatheodoridis, George V.
HEPATOLOGY, 2013, 58 : 697A - 698A
[37] EFFECTIVENESS OF PEGINTERFERON ALFA-2A THERAPY IN HBEAG-POSITIVE AND HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B: FINAL RESULTS 3 YEARS POST-TREATMENT OF THE PROSPECTIVE, GLOBAL, OBSERVATIONAL S-COLLATE STUDY
Marcellin, P.
Xie, Q.
Paik, S. W.
Flisiak, R.
Piratvisuth, T.
Petersen, J.
Asselah, T.
Cornberg, M.
Ouzan, D.
Foster, G. R.
Papatheodoridis, G. V.
Messinger, D.
Regep, L.
Bakalos, G.
Alshuth, U.
Wedemeyer, H.
JOURNAL OF HEPATOLOGY, 2016, 64 : S598 - S599
[38] Baseline and early on-treatment HBsAg level to predict HBsAg loss in nucleotide analog suppressed and HBeAg cleared chronic hepatitis B patients by switching to peginterferon alfa-2a: exploratory results of NEW SWITCH study
Hu, P.
Xie, Q.
Li, Y.
Chen, X.
Dou, X.
Jiang, J.
Shang, J.
Zhang, W.
Gong, G.
Sun, Y.
Li, Y.
Liu, Y.
Liu, G.
Mao, D.
Chi, X.
Tang, H.
Li, X.
Xie, Y.
Chen, X.
Jiang, J.
Zhao, P.
Hou, J.
Gao, Z.
Fan, H.
Ding, J.
Ren, H.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S265 - S265
[39] ADDITION OF PEGINTERFERON ALFA-2a INCREASES HBsAg DECLINE IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY: RESULTS FROM A MULTICENTER RANDOMIZED CONTROLLED TRIAL. (PAS STUDY)
Farag, Mina S.
Fung, Scott K.
Van Campenhout, Margo
Van Erpecum, Karel J.
Wong, David K. H.
Boonstra, Andre
Verhey, Elke
De Man, Robert A.
Liem, Kin Seng
Hansen, Bettina E.
Janssen, Harry L. A.
HEPATOLOGY, 2019, 70 : 127A - 128A
[40] ASSOCIATION BETWEEN TREATMENT OUTCOME AND RS12979860 POLYMORPHISM IN HBEAG POSITIVE AND NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA); AN INTERIM ANALYSIS
Takkenberg, Bart
de Niet, Annikki
Benayed, Ryma
Weegink, Christine J.
Zaaijer, Hans L.
Koot, Maarten
Terpstra, Valeska
Dijkgraaf, Marcel
Jansen, Peter L.
Beld, Marcel
Lopatin, Uri
Reesink, Hendrik W.
HEPATOLOGY, 2010, 52 (04) : 885A - 885A

← 1 2 3 4 5 →